Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

Inclusion Criteria: * Subjects will be outpatients between the ages of 18 and 72. * Subjects must have a biopsy-proven diagnosis of ulcerative colitis for greater than three months. * There should be evidence of active disease with a total Mayo score of 6 to 10 points (scores range from 0 to 12, with higher scores indicating more severe disease activity). * There should be moderate (marked erythema, lack of vascular pattern, friability, erosions) to severe (spontaneous bleeding, ulceration) active disease on colonoscopy (Mayo endoscopic score of at least 2) at time of enrollment. * Laboratory inclusion criteria will require a hemoglobin level of \>9.0 g/dL, a white blood count between 5,000 and 15,000/μL, a platelet count of \>100,000μL, a blood urea nitrogen \< 40mg/dL, a serum creatinine of \<2.0mg/dL, a total bilirubin \< 2.5 mg/dL, and an alkaline phosphatase of \<250U/dL. * Women will be required to have a negative urine pregnancy test and to practice birth control. * The following medications will be allowed and continued throughout the study: Oral or rectal sulfasalazine, mesalamine, or mesalamine derivative (maintenance therapy of \> 8 weeks, stable dose of \> 4 weeks); Oral corticosteroid (prednisone, prednisolone, or budesonide) at an equivalent dose of a maximum of 40mg daily prednisone (maintenance therapy of \>4 weeks, stable dose of \> 2 weeks), azathioprine or 6-mercaptopurine (maintenance therapy of \> 8 weeks, stable dose of \> 4 weeks). * Subjects must have…